Market revenue in 2023 | USD 9.7 million |
Market revenue in 2030 | USD 13.1 million |
Growth rate | 4.5% (CAGR from 2023 to 2030) |
Largest segment | Phase iii |
Fastest growing segment | Phase I |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Phase I, Phase II, Phase III, Phase IV |
Key market players worldwide | Novartis AG ADR, Labcorp Holdings Inc, Medpace Holdings Inc, Charles River Laboratories International Inc, Icon PLC, GlaxoSmithKline Consumer Healthcare (GSK CH India), Aurora Innovation Inc Class A, Biogen Inc, IQVIA Holdings Inc, inVentiv Health |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to neurology clinical trials market will help companies and investors design strategic landscapes.
Phase iii was the largest segment with a revenue share of 46.39% in 2023. Horizon Databook has segmented the UAE neurology clinical trials market based on phase i, phase ii, phase iii, phase iv covering the revenue growth of each sub-segment from 2018 to 2030.
In UAE, the clinical research sector is performing well, with many pharmaceutical companies investing in studies. The Phase III and Phase IV studies are most common in UAE along with observational studies. The regulatory scenario in the country is favorable for clinical studies. The Health Authority Abu Dhabi’s (HAAD) medical research sections promote world-class research that improves health & quality of life while ensuring ethical conduct of research & protection of human subjects.
In 2018, the UAE performed 57 clinical trials, representing 6.2 people per million of total population, which is the highest figure in MEA. Moreover, the time for approval ranges from 30 days to 90 days. These factors are expected to boost the market in the UAE. Furthermore, the country has recently witnessed a rise in the prevalence of neurological disorders.
For instance, the Lancet published a study in 2022 regarding the prevalence of dementia. The study stated that the UAE was ranked second with the highest percentage of people suffering from dementia. The high prevalence of dementia is expected to boost the demand for dementia research in the country, which in turn is expected to promote the growth of neurology clinical trials market in the UAE.
Horizon Databook provides a detailed overview of country-level data and insights on the UAE neurology clinical trials market , including forecasts for subscribers. This country databook contains high-level insights into UAE neurology clinical trials market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account